AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

In a note released Monday, Cantor said that a "major overhang" has been removed for Bristol Myers's (BMY) new schizophrenia drug Cobenfy. Bristol Myers's "biggest competitive threat in ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

It is the first antipsychotic drug approved to treat schizophrenia ... of action than ABBV’s emraclidine. Cobenfy is aimed at treating schizophrenia by selectively targeting M 1 and M 4 ...

Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).

The upgrade comes after AbbVie (ABBV) announced Monday that its schizophrenia ... peak Cobenfy sales to exceed $10B if the company succeeds in adding label expansions to the drug.

It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care. However, BMY’s ...